When was Azor Biotek founded?

Azor Biotek was founded in 2019.

Where is Azor Biotek located?

Azor Biotek is headquartered in Victoria, Canada.

Who is the current CEO of Azor Biotek?

Brock Schuman of Azor Biotek. They have also founded 1 company.

How many employees does Azor Biotek have?

As of Jul 01, 2024, the latest employee count at Azor Biotek is 1 - 10.

Is Azor Biotek a funded company?

Azor Biotek is a funded company, having raised a total of $***** in its 1st and only funding round.

Where does Azor Biotek rank among its competitors?

Azor Biotek ranks 63rd amongst 158 active competitors, of which 64 are funded. It stands 11th in terms of total funding among its competitors. The most recent competitor to raise funding was Evotec, which secured an undisclosed amount in Jan, 2026.

Who are the top competitors of Azor Biotek?

Azor Biotek's top competitors include Evotec, Insitro and DNAnexus. Among them, Evotec secured the most recent funding round in January, 2026.

Azor Biotek - 2026 Company Profile, Team & Competitors

Company Details

AI guided drug design for small molecules targeting RNA/protein interfaces. It develops an AI guided suite to generate novel small molecule entities targeting biological complexes at RNA-protein interfaces. The software suite includes systems biology target analysis, library generation, virtual screening, and hit optimization. It focuses on stabilized RNA/protein interfaces, allowing for the design of novel molecules to target any RNA. Early screening in zebrafish selects for therapeutics with bioactivity and allows for in vivo quantification of concrete physiological hallmarks.

Website: azorbiotek.ca
Phone Number: +1 **********

Key Metrics

Founded Year

2019

Location

Victoria, Canada

Stage

Unfunded

Ranked

63^rd among 158 active competitors

Employee Count

1 - 10 as on Jul 01, 2024

Similar Companies

Evotec & 182 more

View Azor Biotek's full profile

Azor Biotek has not raised any funding rounds yet.

The founders of Azor Biotek are Brock Schuman and Lubos Marek. Brock Schuman is the CEO of Azor Biotek.

Here are the details of Azor Biotek's key team members:

Brock Schuman: Co-Founder & CEO of Azor Biotek.
Contact Info: 1 email address
Lubos Marek: Co-Founder & COO of Azor Biotek.
Contact Info: 1 email address

View details of Azor Biotek's Founder profiles and Board Members

Azor Biotek's employee count trend

Azor Biotek has 1 - 10 employees as of Jul 24. Here is Azor Biotek's employee count trend over the years:

Uncover Azor Biotek's growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of Azor Biotek include Evotec, Insitro and DNAnexus. Here is the list of Top 10 competitors of Azor Biotek, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Evotec 1993, Hamburg (Germany), Public	Provider of drug discovery alliance and development services for biopharma sector	$25M	TVM Capital Life Science, Ventech & 20 others	76/100
2nd	Insitro 2018, San Francisco (United States), Series C	Developer of machine learning platform for drug discovery and development	$643M	Andreessen Horowitz, Google Ventures & 18 others	71/100
3rd	DNAnexus 2009, Mountain View (United States), Series H	Provider of cloud-based genome informatics & data management platform	$473M	Google Ventures, TPG & 21 others	70/100
4th	Cytel 1987, Cambridge (United States), Acquired	Provider of data analysis and statistical solutions for the life sciences industry	$2M	Autonomy Ventures, Merck & 3 others	66/100
5th	Immunai Technologies 2018, United States, Series B	Developer of next-generation of immunomodulatory therapeutics	$295M	TLV Partners, Catalio Capital Management ... & 14 others	66/100
6th	Metagenomi 2016, Berkeley (United States), Public	Digital gene editing technologies for drug development	$376M	Humboldt Fund, RA Capital Management & 22 others	65/100
7th	NewLimit 2022, San Francisco (United States), Series B	Developer of epigenetic reprogramming medicines for aging-related diseases and healthspan extension	$247M	Lilly, Kleiner Perkins & 17 others	64/100
8th	Asimov 2017, Boston (United States), Series B	Provider of integrated suite for advanced genetic design and manufacturing	$209M	Andreessen Horowitz, CPP Investments & 11 others	64/100
9th	Relation Therapeutics 2020, London (United Kingdom), Seed	AI-based drug development tools for researchers	$116M	DCVC, Magnetic Ventures & 9 others	63/100
10th	Kinomica 2017, Macclesfield (United Kingdom), Series A	Provider of a bioinformatics platform for the development of precision medicine	$5.16M	BGF, Longwall Venture Partners & 15 others	63/100
63rd	Azor Biotek 2019, Victoria (Canada), Unfunded	AI guided drug design for small molecules targeting RNA/protein interfaces	-	-	33/100